Review



fate1 targeted shrnas  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Addgene inc fate1 targeted shrnas
    Fig. 1: <t>FATE1</t> is a Target of the Oncogenic Transcription Factor EWSR1-FLI1. (A) FATE1 607
    Fate1 Targeted Shrnas, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fate1+targeted+shrnas/pmyc-GFP-TNRC6A-(1027-1076)+(Plasmid+%2342019)/10__1128_slash_mcb__00138___19-175-12-56
    Average 91 stars, based on 4 article reviews
    fate1 targeted shrnas - by Bioz Stars, 2026-10
    91/100 stars

    Images

    1) Product Images from "EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival"

    Article Title: EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival

    Journal: Molecular and Cellular Biology

    doi: 10.1128/mcb.00138-19

    Fig. 1: FATE1 is a Target of the Oncogenic Transcription Factor EWSR1-FLI1. (A) FATE1 607
    Figure Legend Snippet: Fig. 1: FATE1 is a Target of the Oncogenic Transcription Factor EWSR1-FLI1. (A) FATE1 607

    Techniques Used:

    Fig. 5: FATE1 Destabilizes BNIP3L. (A, B) 72 hours after siRNA transfection, WCLs were collected 655
    Figure Legend Snippet: Fig. 5: FATE1 Destabilizes BNIP3L. (A, B) 72 hours after siRNA transfection, WCLs were collected 655

    Techniques Used: Transfection

    Related Articles

    shRNA:

    Article Title: EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival
    Article Snippet: The insert was ligated into pTA-306 Luc (Clontech) placing the FATE1 promoter insert directly upstream of the luc gene from Photinus 307 pyralis. pFATE1ΔEF1-Luc was produced by amplifying the 1268 base pairs on the 3’-prime end of the 308 FATE1-promoter and then inserting it into pTA-Luc as described for pFATE1-Luc. pRL-CMV 309 expressing Renilla luciferase was a gift from Deborah Chapman, University of Pittsburgh; and pCMV-310 dr8.91 and pCMV-VSV-G were a gift from Michael White (UTSW). psPAX2 and pMD2.G lentiviral 311 constructs were purchased from Addgene. .. For shRNA experiments pLKO.1 vectors from The RNA 312 Consortium (TRC) expressing FATE1 targeted shRNAs (A7: TRCN0000130192 and A9: 313 on M ay 4, 2019 by guest http://m cb.asm .org/ D ow nloaded from 12 TRCN0000146597) were obtained from the UNC Lentiviral core and a non-targeting shRNA in pLKO.1 314 (shSCR) was used as a control (Addgene). ..

    Expressing:

    Article Title: EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival
    Article Snippet: The insert was ligated into pTA-306 Luc (Clontech) placing the FATE1 promoter insert directly upstream of the luc gene from Photinus 307 pyralis. pFATE1ΔEF1-Luc was produced by amplifying the 1268 base pairs on the 3’-prime end of the 308 FATE1-promoter and then inserting it into pTA-Luc as described for pFATE1-Luc. pRL-CMV 309 expressing Renilla luciferase was a gift from Deborah Chapman, University of Pittsburgh; and pCMV-310 dr8.91 and pCMV-VSV-G were a gift from Michael White (UTSW). psPAX2 and pMD2.G lentiviral 311 constructs were purchased from Addgene. .. For shRNA experiments pLKO.1 vectors from The RNA 312 Consortium (TRC) expressing FATE1 targeted shRNAs (A7: TRCN0000130192 and A9: 313 on M ay 4, 2019 by guest http://m cb.asm .org/ D ow nloaded from 12 TRCN0000146597) were obtained from the UNC Lentiviral core and a non-targeting shRNA in pLKO.1 314 (shSCR) was used as a control (Addgene). ..

    Control:

    Article Title: EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival
    Article Snippet: The insert was ligated into pTA-306 Luc (Clontech) placing the FATE1 promoter insert directly upstream of the luc gene from Photinus 307 pyralis. pFATE1ΔEF1-Luc was produced by amplifying the 1268 base pairs on the 3’-prime end of the 308 FATE1-promoter and then inserting it into pTA-Luc as described for pFATE1-Luc. pRL-CMV 309 expressing Renilla luciferase was a gift from Deborah Chapman, University of Pittsburgh; and pCMV-310 dr8.91 and pCMV-VSV-G were a gift from Michael White (UTSW). psPAX2 and pMD2.G lentiviral 311 constructs were purchased from Addgene. .. For shRNA experiments pLKO.1 vectors from The RNA 312 Consortium (TRC) expressing FATE1 targeted shRNAs (A7: TRCN0000130192 and A9: 313 on M ay 4, 2019 by guest http://m cb.asm .org/ D ow nloaded from 12 TRCN0000146597) were obtained from the UNC Lentiviral core and a non-targeting shRNA in pLKO.1 314 (shSCR) was used as a control (Addgene). ..



    Similar Products

    fate1 targeted shrnas  (Addgene inc)
    91
    Addgene inc fate1 targeted shrnas
    Fig. 1: <t>FATE1</t> is a Target of the Oncogenic Transcription Factor EWSR1-FLI1. (A) FATE1 607
    Fate1 Targeted Shrnas, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fate1+targeted+shrnas/pmyc-GFP-TNRC6A-(1027-1076)+(Plasmid+%2342019)/10__1128_slash_mcb__00138___19-175-12-56
    Average 91 stars, based on 1 article reviews
    fate1 targeted shrnas - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 1: FATE1 is a Target of the Oncogenic Transcription Factor EWSR1-FLI1. (A) FATE1 607

    Journal: Molecular and Cellular Biology

    Article Title: EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival

    doi: 10.1128/mcb.00138-19

    Figure Lengend Snippet: Fig. 1: FATE1 is a Target of the Oncogenic Transcription Factor EWSR1-FLI1. (A) FATE1 607

    Article Snippet: For shRNA experiments pLKO.1 vectors from The RNA 312 Consortium (TRC) expressing FATE1 targeted shRNAs (A7: TRCN0000130192 and A9: 313 on M ay 4, 2019 by guest http://m cb.asm .org/ D ow nloaded from 12 TRCN0000146597) were obtained from the UNC Lentiviral core and a non-targeting shRNA in pLKO.1 314 (shSCR) was used as a control (Addgene).

    Techniques:

    Fig. 5: FATE1 Destabilizes BNIP3L. (A, B) 72 hours after siRNA transfection, WCLs were collected 655

    Journal: Molecular and Cellular Biology

    Article Title: EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival

    doi: 10.1128/mcb.00138-19

    Figure Lengend Snippet: Fig. 5: FATE1 Destabilizes BNIP3L. (A, B) 72 hours after siRNA transfection, WCLs were collected 655

    Article Snippet: For shRNA experiments pLKO.1 vectors from The RNA 312 Consortium (TRC) expressing FATE1 targeted shRNAs (A7: TRCN0000130192 and A9: 313 on M ay 4, 2019 by guest http://m cb.asm .org/ D ow nloaded from 12 TRCN0000146597) were obtained from the UNC Lentiviral core and a non-targeting shRNA in pLKO.1 314 (shSCR) was used as a control (Addgene).

    Techniques: Transfection